评论
打印
The first several weeks following her ketamine regimen were "the only time I can say I have felt normal" in 15 years, she says. "It's like you have 50 pounds on your shoulders, and the ketamine takes 40 pounds off."
曼宁说，接受氯胺酮治疗的前几周是15年来“我唯一感觉正常的一段时间。就好像你肩膀上有50磅的重物，氯胺酮能减掉40磅。”
She's now back in Maine, and the depression has returned.
现在，她回到缅因州，抑郁情绪也随之返回。
Her current Medicare insurance won't cover ketamine. She lives on $1,300 a month in disability income. "Knowing it is there and I can't have it is beyond frustrating," she says.
她目前的医疗保险不能支付氯胺酮的费用，她每月靠1300美元的残障收入维持生活。“知道有治疗的方法，但我却无法进行治疗，那种心情难以言表，”她说。
Ketamine is considered a "dirty" drug by scientists—it affects so many pathways and systems in the brain at the same time that it's hard to single out the exact reason it works in the patients it does help.
科学家们认为氯胺酮是一种“肮脏”的药物，它同时影响大脑中的许多通路和系统，因此很难找出它对那些治疗有效的患者发挥作用的确切原因。
That's one reason researchers continue to look for better versions of the drug. Another, of course, is that new versions are patentable.
这是研究人员继续寻找更好的药物的一个原因，另一个原因当然是新药物可以获得专利。
Should Johnson & Johnson's esketamine hit the market, the ketamine pioneers and their research institutions stand to benefit.
如果强生公司的艾氯胺酮进入市场，那么使用氯胺酮的先驱者和他们的研究机构将从中受益。
Yale's Krystal, NIH's Zarate, and Sinai's Charney, all of whom are on the patent on Charney's wall, will collect royalties based on the drug's sales.
耶鲁大学的科瑞斯，美国国家卫生研究院的萨拉特和西奈山伊坎学院的查尼，他们的名字都列在查尼办公室那面墙上所挂的专利证书之中，他们将根据药物的销售情况收取专利权税。
J&J hasn't said anything about potential pricing, but there's every reason to believe the biggest breakthrough in depression treatment since Prozac will be expensive.
强生公司没有对定价问题做出任何说明，但有充分的理由相信，自百忧解以来，在治疗抑郁症方面获得最大突破的药物将非常昂贵。
Concerns about the side effects of ketamine-style drugs linger. Some patients taking esketamine have reported experiencing disassociation symptoms.
人们对氯胺酮类药物副作用的担忧仍然存在。一些使用艾氯胺酮的患者报告出现了分离症状。
Johnson & Johnson calls the effects manageable and says they cropped up within an hour of the treatment, a period in which a person on the drug would likely be kept in the doctor's office for monitoring.
强生公司称这些影响是可以控制的，它们会在开始治疗的一小时内突然出现，在这段时间内，用药患者可能留在医生的办公室里接受监控。
Some patients also experienced modest spikes in blood pressure within the first 75 minutes. Nasal-spray dosing brings other issues.
某些患者在最初的75分钟内还会出现轻微的血压飙升，鼻腔喷雾剂给药还会带来其他问题。
The Black Dog Institute in Australia and the University of New South Wales in Sydney, which teamed up to study a nasal-spray form of ketamine, published their findings last March in the Journal of Psychopharmacology.
联合研究鼻腔喷雾剂式氯胺酮的澳大利亚黑狗研究所和悉尼新南威尔士大学，在3月份的《精神药理学期刊》上发表了他们的研究结果。
The researchers found that absorption rates were variable among patients. J&J says its own studies with esketamine contradict these findings.
研究人员发现，患者对药物的吸收率存在差异。强生表示，他们对艾氯胺酮进行的研究与这些研究结果相矛盾。
